Eton Pharmaceuticals demonstrated strong revenue growth and successful product launches, particularly with Increlex and Galzin. However, the company faces challenges with increased operating expenses and a net loss for the quarter. Despite these lowlights, the overall performance and future prospects indicate a positive trend.

Company Guidance -

Q3 2025

During Eton Pharmaceuticals' first quarter 2025 financial results conference call, CEO Sean Brynjelsen highlighted significant growth and strategic initiatives. Eton reported a 117% year-over-year revenue increase to $17.3 million, driven by product sales and licensing revenue. The company emphasized the potential of its new acquisitions, Increlex and Galzin, which have shown promising results, with Increlex reaching over 90 active patients. Eton aims to expand its product reach by harmonizing U.S. and EU labels, potentially benefiting up to 1,000 U.S. patients. The company is also preparing for the launch of ET-400, targeting a significant market opportunity in adrenal insufficiency, with a PDUFA date set for May 28. Eton's robust pipeline and strategic partnerships position it for continued growth, with expectations to reach a $100 million revenue run rate in the near term. Adjusted gross margins are projected to exceed 75% by 2028.

Strong Revenue Growth

Eton Pharmaceuticals reported a first quarter revenue of $17.3 million, an increase of 117% compared to the first quarter of 2024.

Successful Product Launches

The acquisition and relaunch of Increlex and Galzin have been successful, with Increlex reaching over 90 active patients, reversing a declining trend.

Pipeline Advancements

Eton has advanced its pipeline candidates, with two potential approvals expected in the next 9 months, including ET-400 with a PDUFA date of May 28.

Out-licensing of Increlex International Rights

Eton licensed Increlex's international rights to Esteve Pharmaceuticals for $4.3 million, improving profitability and reinvesting in pipeline opportunities.

Strong Cash Flow

Eton generated $2.1 million of operating cash flow during the quarter and finished with $17.4 million of cash-on-hand.

Eton Pharmaceuticals (ETON) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ETON Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	0.10 / -	0.02	―	―	―
Aug 07, 2025	2025 (Q2)	-0.04 / -0.10	-0.12	16.67% (+0.02)	―
May 13, 2025	2025 (Q1)	0.05 / -0.06	-0.03	-100.00% (-0.03)	―
Mar 18, 2025	2024 (Q4)	>-0.01 / -0.02	-0.09	77.78% (+0.07)	―	―
Nov 12, 2024	2024 (Q3)	-0.01 / 0.02	-0.02	200.00% (+0.04)	―
Aug 08, 2024	2024 (Q2)	-0.07 / -0.12	0.18	-166.67% (-0.30)	―
May 09, 2024	2024 (Q1)	-0.07 / -0.03	-0.1	70.00% (+0.07)	―
Mar 14, 2024	2023 (Q4)	-0.04 / -0.09	0.04	-325.00% (-0.13)	―
Nov 09, 2023	2023 (Q3)	-0.10 / -0.02	-0.12	83.33% (+0.10)	―
Aug 10, 2023	2023 (Q2)	-0.09 / 0.18	-0.06	400.00% (+0.24)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ETON Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$15.26	―	―
May 13, 2025	$17.07	$17.12	+0.29%
Mar 18, 2025	$15.29	$14.68	-3.99%
Nov 12, 2024	$9.17	$10.60	+15.59%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.